Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | CA6 | P23280 | 2/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.55 |
| ▸ | CA4 | P22748 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | TASP1 | Q9H6P5 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arsanilic Acid SCHEMBL4837583 | 1.00 | KDM4E (1.00) | KDM4ETSHRRAB9ACA6CA14 | |
| Arsanilic Acid SCHEMBL5051668 | 0.97 | KDM4E (0.95) | KDM4ETSHRRAB9ACA6CA14 | |
| Arsanilic Acid SCHEMBL31473003 | 0.97 | TSHR (0.95) | KDM4ETSHRRAB9ACA6CA14 | |
| Arsanilic Acid SCHEMBL29203957 | 0.91 | TSHR (0.82) | KDM4ETSHRRAB9ACA6CA14 | |
| Arsanilic Acid SCHEMBL29147746 | 0.91 | TSHR (0.82) | KDM4ETSHRRAB9ACA6CA14 | |
| SCHEMBL1527750 | 0.87 | CYP2C19 (0.79) | KDM4ETSHRRAB9ACA6CA14 | |
| SCHEMBL3406380 | 0.87 | CYP2C19 (0.79) | KDM4ETSHRRAB9ACA6CA14 | |
| SCHEMBL22999953 | 0.85 | KDM4E (0.72) | KDM4ETSHRRAB9ACA6CA14 | |
| SCHEMBL886901 | 0.85 | CYP2C19 (0.76) | KDM4ETSHRRAB9ACA6CA14 | |
| SCHEMBL886903 | 0.85 | CYP2C19 (0.76) | KDM4ETSHRRAB9ACA6CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1938 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122059386-A | Method for preparing titanium-doped ferric phosphate from titanium dioxide byproduct ferrous sulfate | 南京锂源纳米科技有限公司 | 2026-05-19 | — | — | CN | claimed |
| CN-122038426-A | Gene combination for degrading organic arsenic, engineering bacterium and application thereof | 山东省医药生物技术研究中心（山东省病毒研究所） | 2026-05-15 | — | — | CN | claimed |
| US-20260115710-A1 | LAMINATE URINALYSIS ASSAY STRIP AND METHODS OF PRODUCING AND USING SAME | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2026-04-30 | — | — | US | claimed |
| EP-4705766-A1 | TEST STRIP DEVICES CONTAINING LOW VOLUMES OF COLORIMETRIC REAGENTS AND METHODS OF PRODUCING AND USING SAME | Siemens Healthcare Diagnostics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4659017-A1 | LAMINATE URINALYSIS ASSAY STRIP AND METHODS OF PRODUCING AND USING SAME | Siemens Healthcare Diagnostics, Inc. (US) | 2025-12-10 | — | — | EP | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| WO-2024226412-A1 | TEST STRIP DEVICES CONTAINING LOW VOLUMES OF COLORIMETRIC REAGENTS AND METHODS OF PRODUCING AND USING SAME | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2024-10-31 | — | — | WO | claimed |
| WO-2024192144-A1 | PYRAZOLOPYRIMIDINES AS ANTIDOTES FOR ARSENICALS | SOUTHERN RESEARCH INSTITUTE (US) | 2024-09-19 | — | — | WO | claimed |
| WO-2024173923-A2 | FEED COMPOSITIONS | SOLUGEN, INC. (US) | 2024-08-22 | — | — | WO | claimed |
| WO-2024163311-A1 | LAMINATE URINALYSIS ASSAY STRIP AND METHODS OF PRODUCING AND USING SAME | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2024-08-08 | — | — | WO | claimed |
| EP-0911031-A2 | Use of arsenic for preparing a medicament for the treatment of premenstrual syndrome | TARELLO, Walter (IT) | 1999-04-28 | — | — | EP | claimed |
| CN-1040214-C | Preparation of 4-hydroxyl-3-nitrobenzene arsonic acid | LABOUR SERVICE CO UNDER SHUIKO (CN) | 1998-10-14 | — | — | CN | claimed |
| US-5770733-A | Medicinal products and pure preparations of melarsomine dihydrochloride, process for obtaining them and intermediate products obtained | RHONE MERIEUX (FR) | 1998-06-23 | — | — | US | claimed |
| CN-1124099-A | Compound additive premix for feed | ZOU XINHUA (CN) | 1996-06-12 | — | — | CN | claimed |
| US-5459263-A | Medicinal products and pure preparations of melarsomine dihydrochloride, process for obtaining them and intermediate products obtained | RHONE MEREIUX (FR) | 1995-10-17 | — | — | US | claimed |
| EP-0160240-B1 | TEST PIECE FOR DETECTING NITRITE | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION (JP) | 1991-07-31 | — | — | EP | claimed |
| US-4631255-A | DIAZOTIZATION, COUPLERS, DYE FORMATION, BACTERIAL DIAGNOSIS | EIKEN KAGAKU KABUSHIKI KAISHA (JP) | 1986-12-23 | — | — | US | claimed |
| EP-0160240-A2 | Test piece for detecting nitrite | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION (JP) | 1985-11-06 | — | — | EP | claimed |
| US-4485093-A | Immunotoxin conjugate which comprises arsanilic acid, useful for treating malignant tumors, particularly pancreatic cancer | RUNGE, RICHARD G. | 1984-11-27 | — | — | US | claimed |
| US-4348389-A | Quinoxaline adducts useful as anthelmintics | INTERNATIONAL MINERALS & CHEMICAL CORP. (US) | 1982-09-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115710-A1 | LAMINATE URINALYSIS ASSAY STRIP AND METHODS OF PRODUCING AND USING SAME | KLK3, ATP6V1B1, SLC14A1 | KDM4E 2302/4885TSHR 3970/4885RAB9A 1602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.